PEGylation

PEGylation is the covalent conjugation of one or more polyethylene glycol (PEG) moieties to a therapeutic peptide or protein. Since the 1990s it has become one of the most effective chemical modification strategies to extend plasma half-life of parenterally administered biomolecules and mitigate their immunogenicity.

Polyethylene glycol is a linear or branched polymer obtained by ethylene oxide polymerization, with typical molecular weights of 5 to 40 kDa. Its flexible, highly hydrated structure (each ethoxy unit binds 2 to 3 water molecules) forms an "aqueous shell" around the peptide that increases its apparent hydrodynamic radius, reduces glomerular elimination (kidney filtration is limited for objects >60 kDa effective size), and masks sites recognized by proteases and antibodies.

Conjugation chemistry uses activated PEGs bearing a reactive group specific to a peptide chemical function. Most common include: PEG-NHS (N-hydroxysuccinimide ester) to target primary amines (lysine, N-terminus), PEG-maleimide for thiols (cysteine), PEG-aldehyde via reductive amination to selectively target the N-terminus at acidic pH, PEG-azide for click chemistry with alkynes, and PEG-hydrazide for carbonyls. More recent strategies (click chemistry, "releasable PEG") allow site-specific control and, in some cases, slow release of the active peptide.

Documented pharmacokinetic benefits include: half-life extension by a factor of 5 to 100, reduction of toxic plasma peaks, longer dosing intervals (weekly or monthly), and decreased immunogenicity through the so-called "stealth effect". Clinical forms have existed for decades: PEG-interferon α-2a (Pegasys), PEG-adenosine deaminase (Adagen), PEG-asparaginase, PEG-filgrastim (Neulasta), and several PEGylated anticoagulants or growth hormones.

Recent limitations are well characterized: anti-PEG antibodies are present in a growing fraction of the general population (environmental exposure via cosmetics and laxatives), long-term tissue accumulation (cellular vacuolization described in some organs), and reduction of intrinsic activity due to partial masking of functional epitopes. Alternatives such as XTENylation (fusion with unstructured hydrophilic recombinant polypeptides) or lipid acylation (albumin binding) are being developed to bypass these limitations while preserving pharmacokinetic benefits.